Kymera Therapeutics Inc
$ 89.86
1.51%
14 Apr - close price
- Market Cap 7,227,801,000 USD
- Current Price $ 89.86
- High / Low $ 90.08 / 88.55
- Stock P/E N/A
- Book Value 19.42
- EPS -3.69
- Next Earning Report 2026-05-08
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.26 %
- 52 Week High 103.00
- 52 Week Low 24.43
About
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$119.14
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-10-29 | 2025-08-11 | 2025-04-30 | 2025-02-20 | 2024-10-31 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.97 | -0.94 | -0.95 | -0.82 | -0.89 | -0.82 | -0.58 | -0.62 | -0.25 | -0.9 | -0.67 | -0.7 |
| Estimated EPS | -0.79 | -0.8613 | -0.83 | -0.73 | -0.7882 | -0.84 | -0.68 | -0.73 | -0.4 | -0.64 | -0.71 | -0.68 |
| Surprise | -0.18 | -0.0787 | -0.12 | -0.09 | -0.1018 | 0.02 | 0.1 | 0.11 | 0.15 | -0.26 | 0.04 | -0.02 |
| Surprise Percentage | -22.7848% | -9.1374% | -14.4578% | -12.3288% | -12.9155% | 2.381% | 14.7059% | 15.0685% | 37.5% | -40.625% | 5.6338% | -2.9412% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-08 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.89 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KYMR
2026-04-14 16:40:44
Kymera Therapeutics (KYMR) shares rose 4% after the FDA granted Fast Track designation to its lead candidate, KT-621, for treating moderate-to-severe eosinophilic asthma. KT-621, a first-in-class oral degrader of STAT6, is also being evaluated for atopic dermatitis, with promising results from earlier studies. This designation is expected to accelerate its development for a range of inflammatory diseases.
2026-04-13 12:09:37
Kymera Therapeutics (KYMR) has received Fast Track Designation from the FDA for its oral medication, KT-621, for the treatment of moderate to severe eosinophilic asthma. This designation will expedite the development and review process for the drug, which is currently in Phase 2b clinical trials. Despite this positive development, the company's high price-to-sales ratio and recent insider selling activity suggest a mixed picture for investors.
2026-04-13 11:13:00
Kymera Therapeutics announced that its oral STAT6 degrader, KT-621, has received FDA Fast Track designation for moderate to severe eosinophilic asthma. The company is conducting two global Phase 2b clinical trials for KT-621 in asthma and atopic dermatitis, with results anticipated in late 2027 and mid-2027 respectively. This designation could accelerate the development and approval process for KT-621, which aims to address the unmet need for convenient oral treatments for Type 2 inflammatory diseases.
2026-04-13 11:09:37
Kymera Therapeutics has received FDA Fast Track designation for its investigational oral drug KT-621, intended for moderate to severe eosinophilic asthma. This designation aims to accelerate the development and review of KT-621, which is a first-in-class oral STAT6 degrader, currently in Phase 2b clinical trials for both asthma and atopic dermatitis. Earlier studies showed promising results in reducing Type 2 inflammatory biomarkers, and the company anticipates Phase 2b data readouts by mid-2027 for AD and late-2027 for asthma.
2026-04-13 11:09:37
Kymera Therapeutics announced that the U.S. FDA has granted Fast Track designation to KT-621, its first-in-class oral STAT6 degrader, for the treatment of moderate to severe eosinophilic asthma. This designation aims to accelerate the development and review process for KT-621, which is currently undergoing Phase 2b trials for both asthma and atopic dermatitis. KT-621 offers the potential for a convenient oral treatment for patients with Type 2 inflammatory diseases who currently have limited effective options.
2026-04-13 10:10:33
Kymera Therapeutics announced that Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class oral CDK2 molecular glue degrader, triggering a US$45 million milestone payment. This brings Kymera's total collaboration payments from Gilead to US$85 million, with potential for up to US$750 million plus royalties. The event reinforces Kymera's scientific validation and boosts its balance sheet but doesn't alter the near-term focus on KT-621 clinical readouts or the risks associated with high R&D spend and reliance on partners.
